Menu Search
Equities

Lexicon Pharmaceuticals Inc

LXRX:NSQ

Lexicon Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.7474
  • Today's Change-0.024 / -3.16%
  • Shares traded1.03m
  • 1 Year change-32.06%
  • Beta1.1306
Data delayed at least 15 minutes, as of Nov 22 2024 14:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Lexicon Pharmaceuticals Inc had net income fall 73.74% from a loss of 101.94m to a larger loss of 177.12m despite a 766.19% increase in revenues from 139.00k to 1.20m.
Gross margin93.54%
Net profit margin-4,138.33%
Operating margin-4,037.43%
Return on assets-72.42%
Return on equity-136.09%
Return on investment-81.77%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Lexicon Pharmaceuticals Inc fell by 23.88m. Cash Flow from Financing totalled 187.96m or 15,611.30% of revenues. In addition the company used 161.90m for operations while cash used for investing totalled 49.94m.
Cash flow per share-0.7424
Price/Cash flow per share--
Book value per share0.4938
Tangible book value per share0.3706
More ▼

Balance sheet in USDView more

Lexicon Pharmaceuticals Inc has a Debt to Total Capital ratio of 35.88%, a lower figure than the previous year's 71.15%.
Current ratio7.45
Quick ratio7.43
Total debt/total equity0.5596
Total debt/total capital0.3588
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -30.22%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		0.602
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.